JSPR · Jasper Therapeutics, Inc.
$0.60
-0.03 (-5.21%)
At close · Jul 29
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$17.72M
Shares
28.00M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.60
Open$0.63
Day$0.60–0.67
52W$0.32–3.15
Avg vol 30d2.3M
Short int1.7M · 5.9% float · 1.9d
Short vol29%
Last earningsJun 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−53%
below
Price vs 50-day avg
−2%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+43%
trailing
6-month return
−57%
trailing
YTD return
−67%
this year
Relative strength
−63%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
1 of 59 funds reported for Jun 30 · net -1 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.94% of float · ▼ -2.4% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
59 holders — mid 2-yr range
Squeeze score
55
elevated · 0–100
Fundamentals
EPS growth
+19%
Y/Y
Balance sheet
$28.7M
net cash
Quant / Vol
risk profile
Volatility
99%
annualized · 1-yr
Max drawdown
−89%
past year
ATR
17.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−53%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
1 of 59 funds reported for Jun 30 · net -1 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.94% of float · ▼ -2.4% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
59 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $0
Now $1 · 10%
52-wk high $3
vs 200-day avg -53%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JSPR
this stock
Jasper Therapeutics, Inc.
|
$17.72M | -67.2% | — | — | 5.9% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JSPR | -19.5% | +42.5% | -56.5% | +42.5% | -67.2% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -17.1% | +44.8% | -62.8% | +44.8% | -74.2% |